CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
October 2023—Pillar Biosciences announced the global launch of OncoReveal Core LBx, a research use only, liquid biopsy–based next-generation sequencing kit for pan-cancer tumor profiling. The panel interrogates 104 clinically relevant genes in one multiplex reaction, analyzes cfDNA present in plasma for genetic alterations in cancer, including assessment of microsatellite instability, and can batch more than 20 clinical samples on a single Illumina NextSeq run. Mutation detection performance is as low as 0.1 percent.
“We are excited to launch OncoReveal Core LBx, specifically designed to meet the emerging needs of local laboratories looking for scalable and efficient NGS-based liquid biopsy testing solutions,” Randy Pritchard, CEO of Pillar Biosciences, said in a press statement. “Currently, both clinicians and their patients are dependent on large national commercial reference labs to perform liquid biopsy testing, which is both expensive and delays treatment decisions. By enabling local and regional laboratory customers with in-house NGS capabilities for liquid biopsy, Pillar Biosciences can help ensure cancer patients are receiving the quality clinical testing they deserve in a more timely and cost-effective manner, leading to improved treatment decisions and clinical outcomes.”
The panel is powered by PiVAT, an automated secondary bioinformatics software that supports the identification of somatic mutations from cell-free DNA with high sensitivity and specificity. It is compatible with third-party clinical reporting solutions.
Pillar Biosciences, 508-655-3027